Program Director/Principal Investigator (Last, First, Middle): Muttil, Pavan

Biographical Sketch Format Page Program Director/Principal Investigator (Last, First, Middle): Muttil, Pavan BIOGRAPHICAL SKETCH

NAME POSITION TITLE

Muttil, Pavan Assistant Professor of Pharmacy

eRA COMMONS USER NAME- PMuttil

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) INSTITUTION AND LOCATION DEGREE MM/YY FIELD OF STUDY (if applicable) Dr. K. N. Modi Institute of Pharmaceutical and B. S. 08/99 Pharmacy Educational Research, U.P., India Birla Institute of Technology and Science, Pilani, M.S. 07/01 Pharmacy Rajasthan, India Central Drug Research Institute, Lucknow, U.P., Ph.D. 06/06 Pharmaceutics India Division of Molecular Pharmaceutics, Univ. of Post-Doc. 12/09 Pharmaceutics North Carolina at Chapel Hill

A. Personal Statement The objective of the proposed research is to deliver effective doses of aerosolized chemotherapeutic agents precisely to the cancerous regions of the lung without increasing the side effects observed with currently administered agents. This will be achieved by targeting magnetically responsive dry powders containing chemotherapeutic agents to desired regions of the lung using a magnetic gradient field. I am an Early Stage Investigator who is highly motivated to pursue an academic research career. The expertise needed to carry out the proposed research began to develop while I was under the mentorship of Dr. Amit Misra at Central Drug Research Institute, India, pursuing my graduate studies. My training in preparing dry powder formulations for aerosolized therapy and evaluating their efficacy in animal models continued under the guidance of Dr. Anthony Hickey at University of North Carolina at Chapel Hill during my post-doctoral research. Drs. Misra and Hickey are both leading experts in aerosol drug/vaccine delivery to and disposition in the lungs for the treatment of various diseases. I have extensive experience in preparing and characterizing dry powders containing drugs and vaccines for different diseases, and measuring their efficacy in animal models. All these studies matured into peer-reviewed research publications (see section C, below). Because of this background and experience I feel well prepared to carry out the research proposed above, which is an extension of work that I pursued for my graduate and post-doctoral research. In addition to having the necessary expertise to be successful with the proposed research, I offer leadership and administrative skills that were developed during my tenure as a post-doctoral fellow (see section B, honors and awards). These will enhance my effectiveness as a PI, in my opinion. In summary, I have had a long-standing interest in research during my training, with demonstrated research productivity during that time. I am prepared to conduct this research and look forward to having the opportunity to do so.

Biographical Sketch Format Page Program Director/Principal Investigator (Last, First, Middle): Muttil, Pavan B. Positions and Honors Positions/ affiliations January 2010- Present: Assistant Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM 2010-present, Full member, UNM Cancer Center 2010-present, School of Engineering Nanoscience and Microsystems Engineering (NSMSE) graduate program 2011-present, UNM Center for Infectious Disease and Immunity Signature Research Program 2011-present, UNM NCI New Mexico Cancer Nanotech Training Center (CNTC) 2011-present, UNM Biomedical Sciences Graduate Program Professional Membership: 2007-Present- Member, American Association of Pharmaceutical Scientists 2010- Present- American Association of Colleges of Pharmacy Honors and awards: 2012 Bill & Melinda Gates Grand Challenges Exploration Funding 2009 Post-doctoral award for outstanding contributions in Mentoring, Service, and Leadership, University of North Carolina at Chapel Hill 2002-2006 New Millennium Indian Technology Leadership Initiative (NMITLI) Scholarship, Council of Scientific & Industrial Research (CSIR), India 2000 Graduate Aptitude Test in Engineering (GATE) scholarship, India C. Peer-Reviewed Publications/ Patents 1.A. McBride, E. Weeda, T. Anderson, B. Gershman, H. Bowles, D. MacKenzie, J. Norenberg, T. Thompson, P. Muttil Lung cancer cells stably expressing a sodium iodide symporter for high-resolution deep-tissue SPECT/CT imaging of xenografts (Manuscript in preparation- Target journal- Molecular Imaging and Biology) 2.McBride, D. N. Price, L. R. Lamoureux, A. A. Elmaoued, J. M. Vargas, N. L. Adolphi and P. Muttil Preparation and characterization of novel inhalable nano-in-microparticles for site-specific pulmonary drug delivery Molecular Pharmaceutics (submitted) 3.A. McBride and P. Muttil A pilot study targeting Nano-in-Microparticles (NIMs) in rat lungs ex vivo. In: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, editors. Respiratory Drug Delivery. Davis Healthcare International Publishing, LCC. River Grove, IL. 2013 (in press) 4.A. McBride, L. R. Lamoureux, D. N. Price and P. Muttil Novel preparation and characterization of magnetic nano-in-microparticle dry powders for directed drug delivery: an application to lung cancer. In: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, editors. Respiratory Drug Delivery 2012. Davis Healthcare International Publishing, LCC. River Grove, IL. 2012 (Book Chapter) 5.L. Garcia-Contreras, P. Muttil, J. Fallon, M. Kabadi, R. Gerety, and A. Hickey Pharmacokinetics of Sequential Doses of Capreomycin Powder for Inhalation in Guinea Pigs, Antimicrobial Agents and Chemotherapy (2012) Feb 13, 56 (5) 6.C. Wang, L. Garcia-Contreras, P. Muttil, A. Hickey Isoxyl assays in plasma, Journal of Pharmaceutical and Biomedical Analysis (2012) 60, 1-6 7.P. Muttil, D. N. Price, A. McBride

Biographical Sketch Format Page Program Director/Principal Investigator (Last, First, Middle): Muttil, Pavan Pulmonary immunization for TB with live cell-based vaccines: the importance of the delivery route (Editorial), Therapeutic Delivery (2011) 2(12), 1519-1522 8.R. Sharma, A. B. Yadav, P. Muttil, H. Kajal and A. Misra Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis (2011) 91 (1), 107-110 9.L. Garcia-Contreras, P. Muttil, J.K. Fallon, M. Kabadi, R. Gerety and A.J. Hickey “Preclinical Studies of Capreomycin Dry Powder Aerosols for the Treatment of Tuberculosis. In: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S. Farr and P.M. Young, editors. Respiratory Drug Delivery 2010. Vol. 3. Davis Healthcare International Publishing, LCC. River Grove, IL. 2010 (Book chapter) 10. P. Muttil, B. Pulliam, L. Garcia Contreras, J. Fallon, C. Wang, A.J. Hickey and D. A. Edwards Pulmonary Immunization of Guinea Pigs with Diphtheria CRM-197 antigen as Nanoparticle Aggregate dry-powders enhance Local and Systemic Immune Responses. AAPS journal (2010) 12 (4), 699-707 11. P. Muttil, C. Prego, L. Garcia Contreras, B. Pulliam, J. Fallon, C. Wang, A.J. Hickey and D. A. Edwards Immunization of guinea pigs with novel Hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS journal (2010) 12 (3), 330-337 12. D. Lu, L. Garcia Contreras, P. Muttil, D. Padilla, D. Xu, J. Liu, M. Braunstein, D. N. McMurray, A. J. Hickey Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS journal (2010) 12 (3), 338-347 13. A. B. Yadav, P. Muttil, A. K. Singh, R. K. Verma, M. Mohan, A. K. Agrawal, A. S. Verma, S. K. Sinha, A. Misra Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis (2010) 90 (3), 188-196 14. L. Garcia-Contreras, P. Muttil, J.K. Fallon, M. Kabadi, R. Gerety and A. J. Hickey “Preclinical Studies of Capreomycin Dry Powder Aerosols for the Treatment of Tuberculosis”. In: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S. Farr and P.M. Young, editors. Respiratory Drug Delivery. Davis Healthcare International Publishing, LCC. River Grove, IL. 2010 15. L. Garcia-Contreras, J. C. Sung, P. Muttil, D. Padilla, M. Telko, J. L. VerBerkmoes, K. J. Elbert, A. J. Hickey, and D. A. Edwards Dry powder PA-824 aerosols for the treatment of tuberculosis in guinea pigs Antimicrobial Agents and Chemotherapy (2010) 54 (4), 1436-1442 16. P. Muttil, C. Wang, A.J. Hickey Inhaled drug delivery for tuberculosis therapy (Expert review). Pharmaceutical research (2009) 26 (11), 2401-2416 17. A. B. Yadav, R. Sharma, P. Muttil, A. K. Singh, R. K. Verma, M. Mohan, S. K. Patel, A. Misra. Inhalable microparticles containing isoniazid and rifabutin target macrophages and "Stimulate the Phagocyte" to achieve high efficacy. Indian J Exp Biol (2009) 47 (06), 469-474 18. C. Wang, P. Muttil, D. Lu, A. Beltran-Torres, L. Garcia-Contreras and A.J. Hickey. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. AAPS journal (2009) 11(1),139-47 19. L. Garcia- Contreras, Y-L Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W.A. Germishuizen, S. Goonesekara, K. Elbert, B.R. Bloom, R. Miller, P.B. Fourie, A.J. Hickey and D. Edwards.

Biographical Sketch Format Page Program Director/Principal Investigator (Last, First, Middle): Muttil, Pavan Immunization by a bacterial aerosol. Proceedings of the National Academy of Science USA (2008) 105 (12), 4656-60 20. J. Kaur, P. Muttil, R. K. Verma, K. Kumar, A. B. Yadav, R. Sharma and A. Misra. A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. European Journal of Pharmaceutical Sciences (2008) 34 (1), 56-65 21. P. Muttil, J. Kaur, K. Kumar, A. B. Yadav, R. Sharma and A. Misra Inhalable microparticles containing large payload of anti-tuberculosis drugs. European Journal of Pharmaceutical Sciences (2007) 32 (2), 140-150 22. R. Sharma, P. Muttil, A. B. Yadav, S. K. Rath, V. K. Bajpai, U. Mani, and A. Misra Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra Journal of Antimicrobial Chemotherapy (2007) 59, 499-506 23. Inventors: H. Sen, S. Jayanthi, R. Sinha, R. Sharma & P. Muttil Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof. United States patent application no: US 2007/ 0154562 A1 Publication date: July 5, 2007 24. Inventors: H. Sen, S. Jayanthi, R. Sinha, R. Sharma & P. Muttil Microspheres of two anti-tubercular drugs and a biodegradable polymer administered by inhalation alone or combined with oral route, and process thereof. World Intellectual property organization no: WO/2005/039529. Publication date: 6 May, 2005

D. Research Support Bill and Melinda Gates Grand Challenges Exploration Muttil (PI) 05/01/12-10/01/13 “Pulmonary BCG Immunization for Uniform Protection against TB” $100,000 total Evaluation of Novel Subunit Tularemia Vaccines in Rat and Non-Human Primate Aerosol Infection Models CBM-VAXBT1 Defense Threat Reduction Agency (DTRA) Muttil (Co-PI) $670,000 total 10/01/12-09-01/17 Research and Allocation Committee (RAC) grant 09/01/12-06- 01/13 Muttil (PI) $15,000 total Departmental Start-Up Funds, University of New Mexico 01/04/10- 06/01/14 Muttil (PI) $220,000 total

Biographical Sketch Format Page